Report Details:
15 Companies Covered
110 Pages
Pune, India, August, 2024 /press release/- Market Research Future Published a Half-Cooked Research Report on Global Skin Biopsy Market Research Report.
Market Synopsis:
Skin biopsy is a diagnostic procedure carried out to detect skin cancer, infections and other diseases and disorders by removing a small patch of skin for examination purpose. Market Research Future (MRFR) has recently published a report asserting that the global skin biopsy market is anticipated to expand at a significant CAGR of 9.4% during the forecast period of 2024-2032.
The increasing application of skin biopsy procedure for the diagnosis of skin cancer, actinic keratosis, dermatitis, psoriasis and skin infections is driving the expansion of the global skin biopsy market owing to the increasing prevalence of these diseases. The rising pollution and water contamination, being some of the significant causes of skin diseases, are resulting in the growing patient pool undergoing skin biopsy procedure, which in turn is fueling the growth of the global skin biopsy market.
The rapid depletion of ozone layer is causing a rise in penetration of ultraviolet rays. Increasing incidences of skin cancer caused due to long-time exposure to these rays is fueling the growth of the global skin biopsy market. The increasing expenditure on medical devices and instruments and introduction of advanced and cost-effective devices are impacting positively on the expansion of the global skin biopsy market.
The increase in geriatric population and inclination towards less invasive medical procedures are some of the crucial factors that are causing the expansion of the global skin biopsy market. On the flip side, lack of awareness regarding the diseases that require skin biopsy for diagnosis and less technological penetration in underdeveloped regions are likely to create hindrance in the growth of the global skin biopsy market during the forecast period.
Market Segmentation:
The global skin biopsy market has been segmented on the basis of type, device, indicator and end-user Based on type, the skin biopsy market is segmented into shave biopsy, excisional biopsy, incisional biopsy and punch biopsy. Based on device, the skin biopsy market is segmented into needle-based biopsy guns, biopsy curettes and punches, guidance systems, biopsy forceps, biopsy needles and others.
Based on indicator, the skin biopsy market is segmented into actinic keratosis, dermatitis, psoriasis, skin infection, cancer, and others. The skin infection segment is sub-segmented into viral infections, deep fungal infections, basal cell carcinoma, squamous cell carcinoma, and melanoma. Based on end-user, the skin biopsy market is segmented into hospitals, dermatology clinics, and others.
Regional Analysis
The global skin biopsy market is segmented into Americas, Europe, Asia Pacific and the Middle East and Africa. The Americas account for the largest share in the global skin biopsy market owing to the increasing prevalence of skin diseases and the presence of large pool of players of the skin biopsy market in this region.
The Europe region accounts for the second largest share in the skin biopsy market due to the increasing demand for technologically advanced and less invasive diagnostic procedures in this region. The Asia Pacific region is anticipated to project the fastest growth in the global skin biopsy market owing to the increasing investment for the development of healthcare sector by incorporation of advanced technology in the emerging economies such as India and China and increasing incidences of cancer and skin diseases in this region. Whereas, the Middle East and Africa region is anticipated to project steady growth in the global skin biopsy market.
Competitive Analysis:
The high demand for technologically advanced and less invasive diagnostic procedures have created large number of opportunities for the players to invest in the global skin biopsy market. The high investment in research and development is strengthening the competition among the players of the global skin biopsy market.
On 12th June 2024, Cook Medical, a leading medical device manufacturer in the global skin biopsy market, has announced that a letter of intent was signed with the Whitaker Park Development Authority Inc. to acquire the long-standing former cigarette facility, R.J. Reynolds building in order to transform it into an advanced medical device manufacturing facility.
The leading players of the global skin biopsy market that are profiled in the report by MRFR are Boston Scientific Corporation (U.S.), Cook Medical (U.S.), BD (U.S.), DTR Medical Ltd (U.K), Devicor Medical Products, Inc. part of Leica Biosystems. (U.S.), Gallini Srl (Italy), Hologic, Inc. (U.S.), and Cardinal Health (U.S.).